Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Is Abaxis one of those stocks right now? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
Abaxis is a member of the Medical sector. This group includes 761 individual stocks and currently holds a Zacks Sector Rank of #6. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. ABAX is currently sporting a Zacks Rank of #2 (Buy).
The Zacks Consensus Estimate for ABAX's full-year earnings has moved 1.44% higher within the past quarter. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
Based on the latest available data, ABAX has gained about 68.19% so far this year. At the same time, Medical stocks have gained an average of 3.25%. As we can see, Abaxis is performing better than its sector in the calendar year.
Breaking things down more, ABAX is a member of the Medical - Products industry, which includes 70 individual companies and currently sits at #100 in the Zacks Industry Rank. On average, this group has gained an average of 12.69% so far this year, meaning that ABAX is performing better in terms of year-to-date returns.
ABAX will likely be looking to continue its solid performance, so investors interested Medical stocks should continue to pay close attention to the company.